Valion Bio, Inc. (VBIO)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 200K 400K 600K Q1 '21: 323K Q2 '21: 268K Q3 '21: 277K Q4 '21: 389K Q1 '22: 428K Q2 '22: 528K Q3 '22: 477K Q4 '22: 408K Q1 '23: 376K Q2 '23: 161K Q3 '23: 282K Q4 '23: 357K Q1 '24: 334K Q2 '24: 140K Q3 '24: 126K Q4 '24: 180K Q1 '25: 70K Q2 '25: 86K Q3 '25: 146K Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25

Gross Profit Quarterly

-180K -120K -60K 0 60K 120K 180K Q1 '21: 22K Q2 '21: -33K Q3 '21: -26K Q4 '21: -2K Q1 '22: 70K Q2 '22: 125K Q3 '22: 63K Q4 '22: 43K Q1 '23: 113K Q2 '23: 61K Q3 '23: 108K Q4 '23: 5K Q1 '24: 167K Q2 '24: 30K Q3 '24: 44K Q1 '25: 50K Q2 '25: 54K Q3 '25: -145K Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q3 '25

Operating Income Quarterly

-7.5M -5M -2.5M 0 2.5M 5M 7.5M Q3 '21: -1.2M Q4 '21: -2.3M Q1 '22: -2.2M Q2 '22: -3M Q3 '22: -2.6M Q4 '22: -2.3M Q1 '23: -2.1M Q2 '23: -2.1M Q3 '23: -1.8M Q4 '23: -2.2M Q1 '24: -1.5M Q2 '24: -1.3M Q3 '24: -1.4M Q4 '24: -298K Q1 '25: -1.4M Q2 '25: -1.7M Q3 '25: -2.5M Q4 '25: -2M Q1 '26: -5.6M Q2 '26: -6.4M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-7.5M -5M -2.5M 0 2.5M 5M 7.5M Q3 '21: -2.3M Q4 '21: -3.7M Q1 '22: -2.2M Q2 '22: -3M Q3 '22: -2.6M Q4 '22: -2.3M Q1 '23: -2.1M Q2 '23: -2.1M Q3 '23: -1.8M Q4 '23: -2.2M Q1 '24: -1.5M Q2 '24: -1.3M Q3 '24: -1.4M Q4 '24: -1.5M Q1 '25: -1.5M Q2 '25: -1.9M Q3 '25: -2.6M Q4 '25: -2.8M Q1 '26: -6.2M Q2 '26: -7.1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

0 150K 300K 450K Q1 '21: 301K Q2 '21: 301K Q3 '21: 303K Q4 '21: 391K Q1 '22: 358K Q2 '22: 403K Q3 '22: 414K Q4 '22: 365K Q1 '23: 263K Q2 '23: 100K Q3 '23: 174K Q4 '23: 352K Q1 '24: 167K Q2 '24: 110K Q3 '24: 82K Q4 '24: 419K Q1 '25: 20K Q2 '25: 32K Q3 '25: 291K Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25

Operating Cash Flow Quarterly

-6M -4M -2M 0 2M 4M 6M Q3 '21: -1.6M Q4 '21: -2.8M Q1 '22: -2.2M Q2 '22: -1.8M Q3 '22: -2.8M Q4 '22: -2.2M Q1 '23: -2.4M Q2 '23: -2.4M Q3 '23: -1.9M Q4 '23: -1.8M Q1 '24: -1.7M Q2 '24: -1.3M Q3 '24: -1.4M Q4 '24: -1.4M Q1 '25: -889K Q2 '25: -1.8M Q3 '25: -2M Q4 '25: -2.3M Q1 '26: -5M Q2 '26: -5.3M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-6M -4M -2M 0 2M 4M 6M Q1 '22: -2.2M Q2 '22: -1.8M Q3 '22: -2.8M Q4 '22: -2.2M Q1 '23: -2.5M Q2 '23: -2.5M Q3 '23: -1.9M Q4 '23: -1.8M Q4 '24: -1.4M Q1 '25: -889K Q2 '25: -1.8M Q3 '25: -2M Q4 '25: -2.3M Q1 '26: -5M Q2 '26: -5.3M Q1 '22 Q3 '22 Q1 '23 Q3 '23 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 3.5M 7M 10.5M Q1 '21: 2.3M Q2 '21: 2.4M Q3 '21: 2.6M Q1 '22: 9.7M Q2 '22: 9.6M Q3 '22: 96.8K Q1 '23: 201.2K Q2 '23: 296.8K Q3 '23: 1.2M Q1 '24: 86.3K Q2 '24: 235.9K Q3 '24: 6.2M Q1 '25: 596.4K Q2 '25: 881.3K Q3 '25: 1.3M Q1 '26: 2.9M Q2 '26: 3.4M Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-210.00 -140.00 -70.00 0.00 70.00 140.00 210.00 Q4 '21: -2.41 Q1 '22: -2.06 Q2 '22: -1.92 Q3 '22: -28.02 Q4 '22: -50.87 Q1 '23: -61.16 Q2 '23: -68.00 Q3 '23: -42.48 Q4 '23: -185.36 Q1 '24: -191.99 Q2 '24: -190.20 Q3 '24: -188.95 Q4 '24: -41.36 Q1 '25: -26.73 Q2 '25: -23.55 Q3 '25: -25.29 Q4 '25: -8.03 Q1 '26: -7.74 Q2 '26: -7.72 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.